TrialBritish journal of cancer2016

Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer.

Christoph Zielinski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.